Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ARGX by emailGet an email when ARGX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ARGX, unsubscribe in one click. Privacy
📣 What ARGX Says Is Next
second half of 2026 · “A Phase 1b alopecia areata trial is ongoing with data expected in the second half of 2026.”
Company press release, Aug 27, 2026 · SEC filing
second half of 2026 · “A Phase 2 celiac disease study has been initiated with data expected in the second half of 2026.”
Company press release, Aug 27, 2026 · SEC filing
second half of this year · “In addition, positive FB102 Phase 1b data in celiac disease was shared last year, with Phase 2 data expected in the second half of this year.”
Company press release, Jul 27, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ARGX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARGX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.